Latest Breaking News On - Professor nicholas lintzeris - Page 1 : comparemela.com

Research Shows Medical Cannabis Treating 2 7 Percent Of Population

Research Shows Medical Cannabis Treating 2 7 Percent Of Population
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.

New south walesIain mcgregorNicholas lintzerisNational drug strategy householdLambert initiativeCannabis as medicineTherapeutic goods administrationLambert initiative for cannabinoid therapeuticsUniversity of sydneyAustralian institute of healthProfessor iain mcgregorAcademic directorCannabinoid therapeuticsNational drug strategy household surveyAustralian instituteMedicine survey

Australian Medical Cannabis Survey: Call For Participants

Researchers from University of Sydney's Lambert Initiative for Cannabinoid Therapeutics have launched a new Cannabis as Medicine survey.

Nicholas lintzerisIain mcgregorLambert initiativeCannabinoid therapeuticsProfessor nicholas lintzeris

Medicinal cannabis driving ban under review in Queensland

The Queensland government is set to review its drug driving laws that could allow drivers with a prescription back onto the road.

New south walesNicholas lintzerisAndrew mahonUniversity of sydneyMain roadsProfessor nicholas lintzeris

Legal use of medicinal cannabis on rise

Legal use of medicinal cannabis on rise
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

New south walesNicholas lintzerisIain mcgregorUniversity of sydney lambert initiativeLambert initiative for cannabinoid therapeuticsTherapeutics goods administrationCannabis as medicine surveySenate inquiryUniversity of sydneyLambert initiativeMedicine surveyHarm reductionProfessor nicholas lintzerisProfessor iain mcgregorAcademic directorCannabinoid therapeutics

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence - Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine - The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment - Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life News provided by Share this article LUND, Sweden, May 10, 2021 /PRNewswire/ Camurus (NASDAQ STO: CAMX) announces today the publication in JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly buprenorphine depot injections (Buvidal

New south walesFredrik joabssonPeter hjelmstrNicholas lintzerisFredrik tibergUnited nationsUniversity of sydneyBusiness developmentDepot evaluationUtilization trialProfessor nicholas lintzerisConjoint professorAddiction medicineTreatment satisfaction questionnaireChief medical officerReported outcomes